BeyondSpring shares surge 18.81% premarket as DUBLIN-3 trial shows Plinabulin+docetaxel improves NSCLC survival.

BeyondSpring (NASDAQ: BYSI) surged 18.81% in premarket trading following the announcement of positive Phase 3 DUBLIN-3 trial results for its lead candidate, Plinabulin, in non-squamous EGFR wild-type NSCLC patients post-anti-PD-(L)1 therapy. The combination of Plinabulin and docetaxel demonstrated a 15.8-month median overall survival (OS) versus 11.7 months with docetaxel alone (HR=0.55), alongside improved progression-free survival (PFS) and objective response rates (ORR). Additional data from the Asian subset of DUBLIN-3, presented at ESMO Asia 2025, reinforced these findings, showing a 10.8-month OS (vs. 8.8 months) and a 3-month median OS benefit in non-squamous subgroups. The drug also reduced grade 4 neutropenia and new brain metastases, positioning it as a differentiated therapy in a treatment-resistant population. These results, coupled with plans for the confirmatory DUBLIN-4 trial, highlight Plinabulin’s potential to address a major unmet need in NSCLC and drive regulatory milestones.